← GRAIL, LLC overview
GRAIL, LLCGRAL

Why is GRAIL, LLC (GRAL) moving?

Q3 2026
▲2▼1

FDA Panel Backs Galleri, but Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri An FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 that benefits outweigh risks. This clears a major hurdle toward expected early-2027 approval and potential Medicare and private insurance coverage.

    This is the biggest new positive catalyst that could drive future revenue and stock price.

  • Strong Sales and Samsung Investment Q2 Galleri volume rose 35% to over 61,000 tests, revenue grew 24% to $42.6 million, and total revenue rose 26% to $44.7 million. Samsung's $110 million equity investment strengthened the balance sheet.

    These new financial and strategic developments show improving business performance and cash position.

  • Securities Fraud Lawsuits Pile Up Lawsuits over alleged misstatements about the failed NHS-Galleri trial kept accumulating, raising legal costs and negative attention. The August 4 lead plaintiff deadline sustained pressure, creating a legal overhang that could weigh on the stock.

    This ongoing legal risk is a key negative factor that could result in penalties and distract management.

August 2026
▲2▼1

FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.

    This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.

  • Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.

    This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.

  • Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.

    This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.

Latest
▲2▼1

FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom

  • FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.

    This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.

  • Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.

    This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.

  • Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.

    This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.

July 2026
▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

▼2

GRAIL's Legal Overhang Deepens as August 4 Deadline Nears

  • Securities Fraud Lawsuits Keep Piling Up Multiple law firms have filed or are investigating securities fraud claims against GRAIL over the failed NHS-Galleri trial. The growing number of suits raises potential legal costs and keeps negative attention on the stock, weighing on the share price.

    This is the main new development this period, with several firms joining and a key deadline approaching.

  • August 4 Lead Plaintiff Deadline Looms Investors have until August 4, 2026 to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the news and may prompt more shareholders to come forward, sustaining pressure on GRAIL's stock.

    The deadline is a specific upcoming event that could drive further negative headlines and investor anxiety.

Q2 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

June 2026
▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

▼2

GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial

  • Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.

    This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.

  • More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.

    Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.

  • Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.

    This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.

© 2026 MarketDXWhy